Praram 9 Hospital Valuation
Is PR9-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PR9-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PR9-R (THB19.4) is trading below our estimate of fair value (THB20.49)
Significantly Below Fair Value: PR9-R is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PR9-R?
Other financial metrics that can be useful for relative valuation.
What is PR9-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿15.25b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.1x |
Enterprise Value/EBITDA | 14.2x |
PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does PR9-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 34.4x | ||
SKR Sikarin | 23.6x | n/a | ฿21.0b |
M-CHAI Mahachai Hospital | 31.3x | n/a | ฿9.0b |
CMR Chiang Mai Ram Medical Business | 36.8x | n/a | ฿8.0b |
MASTER Master Style | 46x | 21.5% | ฿19.2b |
PR9-R Praram 9 Hospital | 27.3x | 11.7% | ฿15.3b |
Price-To-Earnings vs Peers: PR9-R is good value based on its Price-To-Earnings Ratio (27.3x) compared to the peer average (34.4x).
Price to Earnings Ratio vs Industry
How does PR9-R's PE Ratio compare vs other companies in the TH Healthcare Industry?
Price-To-Earnings vs Industry: PR9-R is expensive based on its Price-To-Earnings Ratio (27.3x) compared to the TH Healthcare industry average (26.8x).
Price to Earnings Ratio vs Fair Ratio
What is PR9-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 27.3x |
Fair PE Ratio | 25.5x |
Price-To-Earnings vs Fair Ratio: PR9-R is expensive based on its Price-To-Earnings Ratio (27.3x) compared to the estimated Fair Price-To-Earnings Ratio (25.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.